Foley recently hosted a webinar where Craig Roush and Jonathan Witt broke down the current U.S. Middle-Market M&A ($25 million – $250 million) trends through the third quarter of 2023.
Much has been said about the return of M&A in 2023, and while there are deals happening, it is not the boom that many expected – but there remain promising signs heading into 2024. Additionally, in this changing climate, aspects of middle-market M&A that were once uncommon have begun to standardize and vice versa. Here are some of the key takeaways from the discussion:
- Deal volume is down almost 10% YTD 2023 vs. 2022, and both volume and pricing have been in a downward trend off the peak of 2021 as parties face interest rate- and financing-driven headwinds.
- Despite the downward trend, M&A activity is still above the pre-pandemic levels of 2019, and a backlog of transactions is building that suggests M&A will be resilient heading into 2024. Buyers have record levels of dry powder, and private equity firms, strategic sellers, and family owners all have reasons to look for exits.
- The economic picture may also be brightening as we head into 2024 – inflation appears to be cooling, interest rates may be peaking, and the long-term macroenvironment appears stable.
- In the near term, credit markets continue to see challenges, with deal financing coming at higher prices and sometimes making up a small portion of the debt/equity mix.
- IPO markets, de-SPAC markets, and foreign investment in U.S. companies are all currently down, while increased buyer and government scrutiny has created additional near-term pressures.
- Representation and warranty insurance have become standard. The short-term decline in M&A activity has led to more advantageous policy terms and pricing for buyers as insurers look to fill excess capacity.
If you were unable to join us for this webinar, we encourage you to view the recording. If you have any questions relating to the topics covered, please contact Craig Roush or Jonathan Witt.
Author(s)
Related Insights
April 23, 2026
Health Care Law Today
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next
Effective April 22, 2026, the Acting Attorney General issued a final order placing certain categories of marijuana and marijuana products into Schedule III of the Controlled Substances Act (“CSA”) in accordance with President Trump’s December 18, 2025 Executive Order on Increasing Medical Marijuana and Cannabidiol Research. This is a landmark development in federal drug policy and one that carries significant legal and business consequences for entities in the pharmaceutical, cannabis, healthcare, tax, and regulatory compliance sectors. As with most everything touching marijuana, however, the details matter enormously. Importantly, the Final Order does not broadly reclassify marijuana. Instead, it defines a narrow and conditional rescheduling that includes several important caveats, added steps, and ongoing obligations that affected parties must understand.
April 23, 2026
The Path & The Practice
Episode 136: Chanley Howell, Partner
This episode features a conversation with Chanley Howell. Chanley is a partner and intellectual property lawyer in Foley’s Jacksonville office where his practice focuses on a broad range of technology law matters. In this discussion, he reflects on growing up in Jacksonville, FL, attending Vanderbilt University for undergrad and the University of Florida College of Law.
April 23, 2026
Foley Career Perspectives
BGCA Author Series Brings Creativity and Empowerment to Boston Club Kids
Foley & Lardner’s national partnership with Boys & Girls Clubs of America (BGCA) is driven in our 25 North American offices through the commitment and support of our attorneys and business professionals who create unforgettable experiences for youth at local Clubs.